AGN Allergan plc

215.00
-6.54  -3%
Previous Close 221.54
Open 222.08
Price To book 1.02
Market Cap 71875830635
Shares 334,306,189
Volume 5,410,678
Short Ratio 3.00
Av. Daily Volume 1,964,164

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171016455
  2. 8-K - Current report 171002923
  3. 8-K - Current report 17976770
  4. 11-K - Annual report of employee stock purchase, savings and similar plans 17927893
  5. SD - 17881547

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

BLA filing announced July 31, 2017.
ABP 980
Herceptin biosimilar
Approval announced March 20, 2017.
JUVÉDERM VOLLURE
Correction of moderate to severe facial wrinkles and folds
Phase 3 trial to be initiated 2H 2017.
Cortisol Analog
Dry Eye disease
Phase 2 top-line data due 2H 2017.
Brimo DDS
Atrophic Age-related macular degeneration (AMD)
Phase 2b data due 2018.
Brazikumab
Crohn's disease
Phase 3 enrollment to be completed 2H 2018.
Bimatoprost
Androgenic Alopecia
Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
Botox
Depression
Phase 3 data due 2H 2018.
Cariprazine
Major depressive disorder (MDD)
Phase 2b trial to be initiated 2H 2017.
RORγt agonist
Psoriasis
sNDA filing acceptance announced March 8, 2017. PDUFA date not noted.
Cariprazine
Schizophrenia/ Negative symptoms
Phase 3 data released March 27 2017 - primary endpoints met. NDA filing due 2H 2017.
Sarecycline
Severe acne vulgaris
Phase 2b top-line data due 1H 2018.
ATOGEPANT
Prophylaxis (migraine)
Phase 3 initiated July 2016. Data due 1H 2018.
UBROGEPANT
Acute (migraine)
Phase 3 initiated October 2016. Data due 2019.
RAPASTINEL
Major depressive disorder (MDD)
Phase 3 to be initiated 2H 2017 with top-line data due 2020.
RELAMORELIN
Diabetic Gastroparesis
Phase 3 data released January 18, 2017 - endpoints met. NDA filing due 2H 2017.
ESMYA (Venus II)
Uterine Fibroids
Phase 3 trial to be initiated 2H 2017.
ABICIPAR
Diabetic macular edema (DME)
Phase 2 two year data due 2H 2017. Phase 3 trial has been initiated.
Cenicriviroc (CVC)
Nonalcoholic steatohepatitis (NASH)
Phase 3 data due 2H 2018.
ABICIPAR
Age-related macular degeneration (AMD)
sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
AVYCAZ (ceftazidime and avibactam)
Complicated Urinary Tract Infections (cUTI)
Approved January 19, 2017.
Oxymetazoline HCl cream 1.0%
Facial Erythema (Redness) Associated with Rosacea
sNDA approval announced January 26, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults
Chronic idiopathic constipation (CIC)
sNDA accepted January 4, 2017. PDUFA estimate September 4 - October 4, 2017.
Liletta
Prevention of pregnancy
Approved September 14, 2017.
MVASITM (bevacizumab-awwb)
Biosimilar candidate to Avastin (bevacizumab)

Latest News

  1. [$$] States Push Ahead With Investigation Into Opioid Painkillers
  2. States expand investigation of opioid makers, distributors
  3. State attorneys general subpoena opioid makers and dealer...
  4. The only thing Trump is doing to end the opioid crisis rewards the companies that started it
  5. Should Value Investors Consider Allergan plc (AGN) Stock Now?
  6. Allergan Innovation Recognized With Three 2017 Allure Best of Beauty Breakthrough Awards
  7. AMD leading IQ100 top gainers
  8. Why Allergan Could Be A $300 Stock
  9. Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle
  10. U.S. senator slams Allergan patent deal with Native-American tribe
  11. U.S. senator slams Allergan tribal patent deal
  12. Amgen/Allergan's Avastin Biosimilar Secures FDA Approval
  13. 3 Dividend Healthcare Stocks
  14. A Biosimilar Cure for Sky-High Cancer Drug Prices
  15. Challenge of Allergan tribal patent deal in uncharted legal territory
  16. Apple, JPMorgan Among Top Picks On New List From UBS
  17. Amgen and Allergan say FDA has approved biosimilar of Roche's Avastin
  18. Allergan plc Ordinary Shares (AGN) May Have Just Saved Itself Billions
  19. FDA Approves Amgen And Allergan's MVASI™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer
  20. These party drugs could become the answer for clinically ...

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171016455
  2. 8-K - Current report 171002923
  3. 8-K - Current report 17976770
  4. 11-K - Annual report of employee stock purchase, savings and similar plans 17927893
  5. SD - 17881547
  6. 8-K - Current report 17874736
  7. 8-K - Current report 17868066
  8. 8-K - Current report 17864899
  9. 8-K - Current report 17862609
  10. 8-K - Current report 17828375